CinCor Pharma EBIT

CinCor Pharma's ebit stands at $-83M as of September 2022. That compares with $-23M in the prior-year period — down 262.1% year over year. That is below the sector sector average of $-63M. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

CinCor Pharma reported $-83M in EBIT versus $-23M a year earlier — a 262.1% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

CinCor Pharma sits lower the its sector benchmark ($-63M) with a EBIT of $-83M. That is roughly 31.9% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

That compares with $-23M in the prior-year period — down 262.1% year over year. Sustained growth in EBIT can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how CinCor Pharma's EBIT evolved across reporting periods, while the comparison chart places CINC next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.